Role of EpCAM + CD133 + extracellular vesicles in steatosis to steatohepatitis transition in NAFLD
Liver International · 2023
DOI: 10.1111/liv.15604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Rocío Muñoz-Hernández und 17 weiteren Autor:innen. Beteiligte Einrichtung: SeLiver Group, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Extracellular Vesicles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Economy, Knowledge, Business and University, Andalusia, Instituto de Salud Carlos III, Junta de Andalucía.
Abstract (Originalsprache)
Background and Aims Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition from simple steatosis to steatohepatitis.
Methods
EpCAM and CD133 liver proteins and EpCAM+ CD133+ EVs levels were analysed in 31 C57BL/6J mice fed with a chow or high fat, high cholesterol and carbohydrates diet (HFHCC) for 52 weeks. The hepatic origin of MVs was addressed using AlbCrexmT/mG mice fed a Western (WD) or Dual diet for 23 weeks. Besides, we assessed plasma MVs in 130 biopsy‐proven NAFLD patients.
Results
Hepatic expression of EpCAM and CD133 and EpCAM+ CD133+ EVs increased during disease progression in HFHCC mice. GFP+ MVs were higher in AlbCrexmT/mG mice fed a WD (5.2% vs 12.1%) or a Dual diet (0.5% vs 7.3%). Most GFP+ MVs were also positive for EpCAM and CD133 (98.3% and 92.9% respectively), suggesting their hepatic origin. In 71 biopsy‐proven NAFLD patients, EpCAM+ CD133+ EVs were significantly higher in those with steatohepatitis compare to those with simple steatosis (286.4 ± 61.9 vs 758.4 ± 82.3; p < 0.001). Patients with ballooning 367 ± 40.6 vs 532.0 ± 45.1; p = 0.01 and lobular inflammation (321.1 ± 74.1 vs 721.4 ± 80.1; p = 0.001), showed higher levels of these EVs. These findings were replicated in an independent cohort.
Conclusions
Circulating levels of EpCAM+ CD133+ MVs in clinical and experimental NAFLD were increased in the presence of steatohepatitis, showing high potential as a non‐invasive biomarker for the evaluation and management of these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SeLiver Group, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.
- Department of Medicine, Dermatology and Toxicology, Universidad de Valladolid / Gastroenterology Unit, Hospital Clínico Universitario de Valladolid / BioCritic, Group for Biomedical Research in Critical Care Medicine, V…
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
ORCID-Profile: Rocío Muñoz-Hernández, Rocío Gallego-Durán, Francisco J Cubero, Javier Vaquero, Manuel Romero-Gómez
Förderung
- Ministry of Economy, Knowledge, Business and University, Andalusia
- Instituto de Salud Carlos III
- Junta de Andalucía
Zitieren
APA
Muñoz-Hernández, R., Gato, S., Gil-Gómez, A., Aller, R., Rojas, A., Morán, L., Gallego, J., Blázquez-López, E., Gallego-Durán, R., Montero-Vallejo, R., García-Fernández, V., Maya-Miles, D., Rico, M. D. C., Cubero, F. J., Vaquero, J., Ampuero, J., Bañares, R., & Romero-Gómez, M. (2023). Role of EpCAM + CD133 + extracellular vesicles in steatosis to steatohepatitis transition in NAFLD. Liver International. https://doi.org/10.1111/liv.15604
Vancouver
Muñoz-Hernández R, Gato S, Gil-Gómez A, Aller R, Rojas A, Morán L, et al. Role of EpCAM + CD133 + extracellular vesicles in steatosis to steatohepatitis transition in NAFLD. Liver International. 2023. doi:10.1111/liv.15604
BibTeX
@article{MuozHernndez2023,
author = {Muñoz-Hernández, Rocío and Gato, Sheila and Gil-Gómez, Antonio and Aller, Rocío and Rojas, Angela and Morán, Laura and Gallego, Javier and Blázquez-López, Elena and Gallego-Durán, Rocío and Montero-Vallejo, Rocío and García-Fernández, Vanessa and Maya-Miles, Douglas and Rico, María Del C and Cubero, Francisco J and Vaquero, Javier and Ampuero, Javier and Bañares, Rafael and Romero-Gómez, Manuel},
title = {Role of EpCAM + CD133 + extracellular vesicles in steatosis to steatohepatitis transition in NAFLD},
journal = {Liver International},
year = {2023},
doi = {10.1111/liv.15604}
}
EUVIMED